NRAS and IRS2

Data Source:
BioGRID (affinity chromatography technology)

		NRAS	IRS2
Description		NRAS proto-oncogene, GTPase	insulin receptor substrate 2
Image
GO Annotations	Cellular Component	Golgi Membrane Golgi Apparatus Plasma Membrane Membrane Extracellular Exosome Tertiary Granule Membrane	Cytosol Plasma Membrane Protein-containing Complex
	Molecular Function	GTPase Activity Protein Binding GTP Binding GDP Binding Protein-containing Complex Binding	Insulin Receptor Binding Protein Binding Protein Kinase Binding Protein Phosphatase Binding Protein Domain Specific Binding Phosphatidylinositol 3-kinase Binding 14-3-3 Protein Binding
	Biological Process	MAPK Cascade Positive Regulation Of Endothelial Cell Proliferation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Neutrophil Degranulation	MAPK Cascade Positive Regulation Of Mesenchymal Cell Proliferation Negative Regulation Of B Cell Apoptotic Process Glucose Metabolic Process Signal Transduction Axon Guidance Brain Development Positive Regulation Of Cell Population Proliferation Insulin Receptor Signaling Pathway Response To Glucose Negative Regulation Of Long-chain Fatty Acid Import Across Plasma Membrane Positive Regulation Of Glucose Metabolic Process Positive Regulation Of Phosphatidylinositol 3-kinase Signaling Regulation Of Lipid Metabolic Process Positive Regulation Of Cell Migration Mammary Gland Development Positive Regulation Of B Cell Proliferation Positive Regulation Of Fatty Acid Beta-oxidation Positive Regulation Of Insulin Secretion Cellular Response To Insulin Stimulus Negative Regulation Of Kinase Activity Interleukin-7-mediated Signaling Pathway Positive Regulation Of Glycogen Biosynthetic Process Positive Regulation Of Glucose Import Positive Regulation Of Ras Protein Signal Transduction Phosphatidylinositol-mediated Signaling Positive Regulation Of Protein Kinase B Signaling Lipid Homeostasis Cellular Response To Glucose Stimulus
Pathways		SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation RET signaling Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Growth hormone receptor signaling
Drugs
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
GWAS		Adult body size ( 32376654) Autism ( 24189344)	Antipsychotic drug-induced weight gain in schizophrenia ( 31447353) Heel bone mineral density ( 30598549 28869591) Hematocrit ( 32888494) Hemoglobin ( 32888494) Hemoglobin levels ( 32327693) High light scatter reticulocyte count ( 32888494) Insulin-related traits (multivariate analysis) ( 32002517) Mean corpuscular hemoglobin ( 29403010 32888494 27863252) Mean corpuscular volume ( 29403010 32888494 27863252) Mean reticulocyte volume ( 32888494) Mean spheric corpuscular volume ( 32888494) Nose size ( 27182965) Paclitaxel disposition in epithelial ovarian cancer ( 29367611) Platelet count ( 29403010) Prostate cancer ( 29117387) Red cell distribution width ( 32888494) Reticulocyte count ( 32888494) Reticulocyte fraction of red cells ( 32888494 27863252) Type 2 diabetes ( 30297969) Vertical cup-disc ratio (multi-trait analysis) ( 31959993) White matter lesion progression ( 26451028) White matter lesion progression (adjusted for white matter lesion burden at baseline) ( 26451028)
Interacting Genes		48 interacting genes: ACVR1 AKT1 ALDOB AOPEP ARAF ARHGAP4 BCL2 CCDC180 CORO2A CYLC2 DNAJB1 EEF1A1 FANCC FBP2 FRAT2 HEMGN HRAS LEF1 LZTR1 MAPK3 MAPKAP1 MTOR PIK3CA PIK3CG PLCE1 PPP2CB RACGAP1 RAF1 RAP1GDS1 RASA1 RASGRP2 RASSF5 RGL2 RGL3 RIN1 RPS20 SFRP4 SHOC2 SMAD1 SMAD4 SMURF2 SRI STX17 TDRD7 TRMO UBE2L3 WDR76 XPA	40 interacting genes: ATP2A1 ATP2A2 BCL2L1 CRK EPOR FES GRB2 IGF1R IL4R INSR JAK1 JAK2 JAK3 MPL MTDH NEDD4 NTRK1 PIK3CA PIK3CD PIK3R1 PIK3R2 PIK3R3 PLCG1 PTPN11 PTPN6 PTPRF RPTOR SHC1 SOCS1 SOCS3 SOCS6 SOCS7 SRPK2 TYK2 UBTF YWHAB YWHAE YWHAG YWHAQ YWHAZ
Entrez ID		4893	8660
HPRD ID		01273	02878
Ensembl ID		ENSG00000213281	ENSG00000185950
Uniprot IDs		P01111 Q5U091	Q9P084 Q9Y4H2
PDB IDs		2N9C 3CON 5UHV 6E6H 6MPP 6ULI 6ULK 6ULN 6ULR 6UON 6WGH 6ZIO 6ZIR 6ZIZ	3FQW 3FQX
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?